TD Cowen analyst Gary Taylor lowered the firm’s price target on Elevance Health (ELV) to $484 from $589 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $478 from $585 at RBC Capital
- Elevance Health cut to Hold at Argus on earnings pressure in 2024-2025
- Elevance Health price target lowered to $520 from $620 at Truist
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health price target lowered to $555 from $605 at UBS